Home > Cardiology > AHA 2020 > Heart Failure > “Strongly consider an SGLT2-inhibitor in most T2DM patients”

“Strongly consider an SGLT2-inhibitor in most T2DM patients”

Presented By
Prof. Deepak Bhatt, Brigham and Women’s Hospital, USA
Conference
AHA 2020
Trial
Phase 3, SOLOIST-WHF; SCORED

[audio mp3="https://conferences.medicom-publishers.com/wp-content/uploads/2021/02/Bhatt-D-et-al-Sotagliflozin-in-Diabetes-Patients.mp3"][/audio]

 

Data from 2 large clinical trials showed new benefits of the dual sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor sotagliflozin for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease as well as those with T2DM and recently worsening heart failure (HF). Both trials were terminated early due to COVID-19-related loss of funding.

Prof. Deepak Bhatt (Brigham and Women’s Hospital, USA) presented results of the SOLOIST-WHF trial (NCT03521934) as well as the SCORED trial (NCT03315143), both of which tested sotagliflozin [1,2]. Results were simultaneously published in the New Engla...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on